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Introduction
A central challenge in life sciences research is to identify modulators of protein-protein interactions (PPIs). 1, 2 Such modulators represent probes with which to uncover new understanding of structural and cellular biology, as well as starting points for drug discovery.
The BCL-2 family of PPIs are an important class of α-helix mediated interaction that control the intrinsic apoptosis pathway. 3 Their critical role in apoptosis has prompted efforts to identify modulators so as to facilitate greater understanding of both BCL-2 family signaling and drug discovery. [4] [5] [6] [7] [8] Moreover differing selectivities and specificities amongst BCL-2 family member interactions 9,10 render the family an outstanding model system to elaborate novel generic chemical and biological approaches for protein-protein interaction modulation. 11, 12 BCL-2 family proteins can be identified through their BH (BCL-Homology) domains and may be categorized within 3 specific sub-groups ( Fig. 1a ). Pro-apoptotic (or executioner) proteins such as BAK and BAX activate apoptosis through pore formation in the mitochondrial membrane; anti-apoptotic proteins including BCL-2, MCL-1 and BCL-xL, sequester pro-apoptotic members to prevent cell death; and a group of regulatory proteins which bind to other BCL-2 members (including BIM, BID, BAD, NOXA and PUMA), mediate initiation of apoptosis. In all cases binding between BCL-2 family members occurs through the BH3 homology domain of one protein, which forms an α-helix upon binding and docks into a complementary cleft on its partner (Fig. 1b) . The BH3 ligand exploits conserved hydrophobic residues in positions i, i + 4, i +7 and i +11 together with a conserved aspartic acid (at i + 9) to achieve high affinity interaction with the BH3 cleft ( Fig. 1c) . In silico and experimental approaches have been used to identify selective sequences for individual BCL-2 family members. [13] [14] [15] [16] Multiple studies have endeavoured to identify chemotypes which mimic the BH3 domains so as to orthosterically inhibit BCL-2/BH3 PPIs including: constrained peptides, [17] [18] [19] [20] [21] [22] [23] peptidomimetics, [24] [25] [26] [27] small molecules [28] [29] [30] [31] and miniature proteins (identified with assistance from biological selection). 32, 33 We have used a previously described Affimer library [34] [35] [36] [37] [38] [39] to identify potent ligands for MCL-1, BCL-xL, BCL-2, BAK and BAX and selective inhibitors of MCL-1 and BCL-xL interactions with cognate BH3 partners.
Our aim was not only to identify high affinity binders, but also to then screen for subsets that would inhibit PPIs, provide multiple sequences for motif identification, and to use those amenable to structural studies to understand the mode of binding. Affimer reagents belong to an emerging class of non-antibody based protein scaffolds which include, Monobodies, Darpins, Affibodies and others, [40] [41] [42] [43] [44] which may offer advantages in therapeutic and diagnostic settings associated with improved solubility, purification, expression and stability.
Affimer reagents are based on either a human scaffold, 45 or a phytocystatin scaffold ( Fig.   1d ) which has been optimized by homology. 39 Both show high thermal stability and achieve molecular recognition through one or two variable regions (VRs) of between six and twelve amino acid residues. Multiple large libraries of Affimers have been established permitting biological selection of optimized binding reagents through randomization within each of the VRs. 39, 46 These reagents provide access to distinct compositional and conformational peptide diversity compared to natural biological peptides, and can be identified via the power of genetics rather than synthetic chemistry.
Results (with subheadings),
Isolating Affimers
Following expression using established methods (see ESI), MCL-1, BCL-xL, BCL-2, BAK and BAX were biotinylated and immobilised on plates, over which the library of Affimers was panned in order to isolate high-affinity binders (see methods). Phage ELISA was then used to identify clones that bind selectively for further analysis. Following this screening, candidate Affimer reagents were sequenced resulting in twelve unique sequences with affinity for MCL-1 (from 24 clones), eleven for BCL-xL (21 clones), four for BCL-2 (20 clones), five for BAX (31 clones) and four for BAK (24 clones). Tables S1 and S2 (see ESI) indicates the identified sequences and frequency.
Binding Analysis of Affimers
Small scale expression of the Affimers then allowed preliminary biophysical/biochemical analyses. For MCL-1 and BCL-xL, single concentration fluorescence anisotropy (FA) competition assays ( Fig. 2 a,b ) against BCL-xL /BAK or MCL-1/NOXA-B (using competitor Affimer at 1 µM) were used to identify Affimers that inhibit cognate BH3 binding. Inhibition was compared to positive controls BAK and ABT-737 for BCL-xL and NOXA-B for MCL-1 with the peptide activity defined as 100% inhibition (note that ABT-737 is more active than BAK therefore achieves 150% inhibition). From these assays, three BCL-xL Affimers were identified with significant inhibitory potency, (BCL-xL-AF6, BCL-xL-AF7 and BCL-xL-AF10) and two MCL-1 Affimers (MCL-1-AF1 and MCL-1-AF11). We did not have an established competition assay for BAK and BAX. BAK, BAX and BCL-2 Affimers were purified by size exclusion chromatography, then confirmation of correct Affimer folding was obtained through circular dichroism (CD, see ESI, Fig. S1 ). Binding ELISA using a primary antibody for the His tag on the Affimer and secondary HRP antibody established potent and selective interaction between the selected Affimer and BCL-2 targets ( Fig. 2 c,d and Fig. S2 ). BCL-2-AF1 to BCL-2-AF3 and BAK-AF1 to BAK-AF4 were confirmed as genuine binders, selective for their targets, but no BAX Affimers were successfully confirmed from the ELISA analyses.
Biophysical Analysis of Affimers
Larger scale expression in E. coli of the five Affimers identified from single point FA competition allowed the purified proteins to be tested in full dose response fluorescence anisotropy competition assays against their target ( Fig. 3 a,b ). BCL-xL-AF10 showed problems during purification so was not further characterized. Both BCL-xL-AF6 (IC50 = 448 ± 53 nM) and BCL-xL-AF7 (IC50 = 393 ±54 nM) were shown to act as sub µM inhibitors of the BCL-xL/BAK interaction ( Fig. 3a ) but were ineffective in inhibiting the MCL-1/NOXA-B interaction. Similarly, the Affimers selected for MCL-1 binding were shown to act as low µM inhibitors of their target interaction (MCL-1-AF1 IC50 = 2.1 ± 0.2 μM; MCL-1-AF11 IC50 = 3.2 ± 0.4 μM) but did not inhibit BCL-xL /BAK, (Fig. 3b ), demonstrating selectivity.
Isothermal titration calorimetry (ITC; Fig. 3c -d, Fig. S3 and Table 1 ) confirmed the conclusions garnered from competition FA and gave Kd values consistent with the determined IC50 values. Both BCL-xL-AF6 (BCL-xL selective) and MCL-1-AF11 (MCL1 selective) Affimers exhibited favourable enthalpic but unfavourable entropic contributions to binding (it was not possible to obtain data for MCL-AF1). In the case of BCL-xL-AF6 a particularly strong enthalpic contribution was observed. On the other hand BCL-xL-AF7 was found to be favourable in both the enthalpic and entropic terms. Given the hydrophobic nature of the BH3 binding cleft and high conservation of aliphatic side chains at key positions in both BH3 sequences and the Affimers (see discussion of co-crystal structure below), the observation that different thermodynamic signatures can be employed to achieve recognition could be a useful consideration in informing inhibitor design. Whilst thermodynamic signatures are notoriously difficult to interpret, and enthalpically driven hydrophobic molecular recognition has been documented, the "classical" view of hydrophobic driven binding is one of entropic desolvation. [47] [48] [49] [50] Moreover, our own prior studies characterized BH3/BCL-2 family interactions as entropically driven. 20 Whilst the Affimer technology regularly produces binders with Kd in the nanomolar range 36 , here we added multiple layers of screening (inhibition of BH3 binding; compatible with anisotropy and ITC experiments) in addition to panning for high affinity binders. This will naturally lead to an attrition rate where clones that do not meet the criteria are lost, which may explain the slightly lower affinities we observe ( Table 1) . We have chosen this approach as the selectivity achieved here is of significantly greater value than affinity alone in experiments where inhibition of a single member of a highly homologous family is desired.
With additional and more stringent panning and selection (potentially quicker), or a larger library or use of affinity maturation techniques (slower), better affinities may be achievable where all criteria are met.
Crystal Structures and Conformational Selection
Having established that Affimers act as selective inhibitors of BCL-2 family PPIs, we attempted to obtain co-crystals to allow high-resolution structural interpretation of the interactions. BCL-xL-AF6/BCL-xL, BCL-xL-AF7/BCL-xL and MCL-1-AF11/MCL-1 cocrystals were obtained (see methods, Table 2 and ESI); and the structures solved by molecular replacement using Phaser. 51 For BCL-xL-AF6/BCL-xL, the crystals diffracted to 1.91 Å, and the asymmetric unit contains one domain swapped dimer of BCL-xL, with one BCL-xL-AF6 bound to the cleft of each monomer (Fig 4 a,c) . For BCL-xL-AF7/BCL-xL, the crystals diffract to 2.24 Å, and the asymmetric unit contains two domain swapped dimers of BCL-xL, with one BCL-xL-AF7
bound to the cleft of each monomer (Fig 4 a,b ). The residues within the VRs of both Affimers interact with residues lining the BH3-binding cleft on the surface of BCL-xL. Representative electron density is presented in Fig. S4 . As expected, given that we selected for competitive Affimers, the Affimers bind at the BH3 binding groove. Indeed, the Affimers use some of the available binding pockets in the groove. In BCL-xL-AF6, F43 binds to the pocket as does F101 on BIM (in PDB 5C3G), and F76 binds the same pocket as I97 on BIM. For BCL-xL-AF7, W41 binds the same pocket as F101 on BIM. However, the universally conserved Asp to Arg hydrogen-bond is not replicated in any way by the Affimer.
On inspection it is apparent that the Affimers are selecting a single conformation of the BCL-xL domain. The binding groove on BCL-xL is formed by helices 3 and 4 ( Fig. 5 ) and helix 3 is mobile such that the width of the groove can vary. When the BIM BH3 peptide is bound, helix 3 moves to accommodate the peptide in a relatively wide groove. By comparison, when BCL-xL is bound to small molecules such as WEHI-539, or to BCL-xL-AF6 and BCL-xL-AF7, the groove is narrow ( Fig. 5 ). When bound to BIM peptide the groove is 16.1 Å wide at the widest point ( Fig. 5a ), whereas in the small molecule and Affimer bound conformation it is 11.0 Å wide ( Fig. 5b ). All four copies of BCL-xL-AF7/BCL-xL in the asymmetric unit have this narrow groove i.e. small molecule conformation, suggesting that this is independent of crystal packing. For clarity, an overlay of the BCL-xL domain only, when in complex with BIM, Affimer and WEHI-539, is presented in Fig. S5 . This suggests that not only are Affimers selecting a single conformation from the multiple dynamic possibilities in solution, but also that they could be used to select a conformation that is desired by the experimenter. In this case, not only does the Affimer bound conformation correspond to the small molecule bound conformation (thus this might be a better starting point for structure based drug design), but it is also a conformation where the binding groove is too narrow to accommodate the BH3 helix, possibly potentiating the orthosteric competitive effect.
For MCL-1-AF11/MCL-1, the crystals diffract to 2.20 Å, and the asymmetric unit contains 4 copies of the complex (Fig 6 a,b ) with representative electron density in Fig. S4 . Again, the competition with BH3 peptide is mediated via VR residues inserted into the binding groove, with W73 of MCL-1-AF11 binding in the same pocket as V85 of NOXA (PDB 2NLA); unsurprisingly, all three crystal structures reveal that the Affimers use the available pockets in the peptide binding site for binding. Again, as for the BCL-xL Affimers, we see that the binding of Affimer selects a desirable conformation. Song et al. 52 have shown that MCL-1 can adopt multiple conformations in solution with differing outcomes in the cell. When BIM BH3 is bound, MCL-1 adopts a non-helical conformation at the QRN motif around Arg222.
By contrast, when bound to Mule BH3 or a range of small molecules, the QRN motif is helical. Critically, when the QRN motif is helical, then ubiquitin can be added at this motif, and this promotes cellular degradation by the proteasome. By both competitively inhibiting BH3 binding at the groove, and promoting degradation in cells, the small molecules dramatically reduce MCL activity in treated cells, promoting apoptosis in MCL dependent cancer cell lines. Interestingly, our structure shows that MCL-1-AF11 also selects the desired helical, ubiquitinatable, conformation, again demonstrating that an Affimer can be isolated that selects a specific desired conformation.
All known biological partners, 4 and indeed all designed peptides thus far, 13, 14, [53] [54] [55] that interact with BCL-2 family proteins at the BH3 groove do so with peptide in a helical conformation. Crucially, the VRs do not adopt an a-helical conformation to make interactions with the BH3 binding cleft (presumably in part because they are constrained from doing so).
Despite the absence of a helical binding conformation, the Affimers project amino acids side chains so as to mimic key hydrophobic and polar contacts made by BH3 ligands and BCL/MCL. Thus, we have identified proteins that binds to the BH3 binding groove via a noncanonical fold. Peptidomimetics based on this structure, rather than the canonical a-helices, may therefore represent a novel starting point for small molecule discovery.
Discussion (without subheadings)
We have used the Affimer libraries to isolate reagents that are highly selective for their targets and can discriminate between very related homologues such as Bcl family proteins and Sumo variants. 35 Given that Affimers express well in live cells, this approach should prove fruitful in identifying reagents that can be used to investigate cell biology that is dependent on related proteins, for instance signalling pathways where there is a need to discriminate the actions of highly related isoforms. 36 Comparison between the Affimer/BCL-xL and BCL-xL/BIM (PDB ID: 1PQ1) structures illuminates key features; the BH3 cleft narrows in response to Affimer binding in contrast to the wider cleft observed for binding of BIM (Fig. 5a ). The BCL-xL conformation in the Affimer bound form is much more similar to that observed for small molecule bound structures such as WEHI-539 (PDB ID: 3ZLR. Fig 5b) , where BCL-xL is also domain swapped.
Similarly, when comparing the structures of MCL-1 bound to peptide vs Affimer we observe that the variable loops of the Affimer are inserted into the BH3 binding groove and that a desirable conformation is selected. In this case, the conformation is remote from the binding These data, and a previous report, 34 imply that Affimers can be used not only to identify selective sequences that differentiate between related family members, but also that they can be used for conformational selection of productive or desirable binding modes. The role of conformational selection in studies of protein-protein interactions is increasingly being recognized. [56] [57] [58] [59] [60] [61] Still, it remains a major challenge to account for protein dynamics in structure-based drug-design. 62 This library of Affimers allows exploration of a dynamic range of protein target conformers, potentially facilitating generation of template pharmacophores for small-molecule ligand design and structure based-ligand design, which may offer an advantage over the current process that typically operates using static crystal structures. 62 In summary, we have identified non-natural protein ligands that exhibit selectivity for different BCL-2 family members. Although computational protein design has been applied to discovery of BCL-2 family selective binders, 63 to our knowledge non-antibody based binding proteins have not previously been shown to differentiate between these proteins notably BCL-xL and MCL-1; this is noteworthy given the role of MCL-1 in driving several cancers. 64, 65 We note the attrition rate that is a consequence of applying a variety of activity criteria as we progressed along this pipeline. Of the 12 MCL-1 and 11 BCL-xL binders identified, not all were inhibitors of the cognate BH3 binding, not all were amenable to biophysical assays, and only three have yielded high resolution crystal structures. This serves as a reminder that a large number of binders is required in order to identify ligands with multiple selection criteria applied.
The co-crystal structure provides inspiration for the structure-based design of peptide and small molecule based BCL-2 family modulators, a goal we will pursue in due course.
Similarly, BCL-2 binding Affimers themselves could be elaborated for therapeutic or diagnostic use. 34, 66 Of potentially equal significance is the observation that non-canonical folds can substitute for native folds in peptide/protein based inhibitors of PPIs 67, 68 ; this is reminiscent of the use of a β-hairpin to mimic an α-helix for p53/hDM2 inhibition. 69, 70 In contrast to those studies, the sequences identified here were obtained under selection pressure, and this poses the question: do BCL-2 family proteins function in cells through molecular modes of interaction other than the canonical α-helix/cleft motif observed to date?
Methods

Overexpression and Purification of BCL-2 Family proteins
BCL-2 family proteins were expressed and purified following previously published methods 20 -a full description is given in the supporting information.
Screening for Affimers
BCL-2 family proteins were biotinylated using EZ-link NHS-SS-biotin (Pierce), according to the manufacturer's instructions. Biotinylation was confirmed using streptavidin conjugated to horseradish peroxidase (HRP). Biotin-BCL-2 family proteins were added and incubated on pre-blocked steptavdin plate, the plate was then washed using a KingFisher robotic platform (ThermoFisher) and 10 12 cfu of the prepanned phage library was added and incubated for 2.5 h with shaking. Wells were wash ten times and eluted with 100 µL 0.2 M glycine (pH 2.2) for ten minutes neutralized with 15 µL 1 M Tris-HCl (pH 9.1), further eluted with triethylamine 100 mM for 6 min, and neutralised with 1 M Tris-HCl (pH 7). Eluted phage were used to infect ER2738 cells for 1 h at 37 °C and 90 rpm then plated onto LB agar plates with 100 µg/ml carbenicillin and grown overnight. All colonies were scrapped into 5 mL of 2XYT with carbenicillin (10 µg/mL) and 1 x 10 9 M13K07 helper phage were added. After an overnight incubation phage were precipitated with 4 % polyethylene glycol 8000, 0.3 M NaCl and resuspended in 1 ml of 10 mM Tris, pH 8.0, 1 mM EDTA (TE buffer). 2 µL phage suspension was used for the second round panning round using streptavidin magnetic beads as opposed to streptavidin plates (Invitrogen); otherwise the second pan was conducted in the same way as the first pan. The third pan was conducting using neutravidin high binding capacity plates (Pierce). After the final pan colonies were picked, an ELISA was conducted to select positive clones (in the same way as the enrichment ELISA) which were sent for Sanger sequencing.
Overexpression and purification of Affimers
The Affimers were subcloned from the phage display vector into pET11a then expressed and purified from E. coli strain Rosetta 2. 10 ml of overnight starter culture was used to Origin software version 7.0 was used to determine the dissociation constants (Kd). All measurements were repeated at least twice. 
Single Point Fluorescence Anisotropy
Competition assays
Competition fluorescence anisotropy assays and data processing were performed adapting previously described protocols. 20 Briefly, the buffer used for fluorescence anisotropy was Crystals grew in 12% PEG 1500, 0.1M Sodium Acetate pH 5.5, 2.5 M NaCl, 1.5% MPD at 20°C at 5mg/ml using the sitting drop vapour diffusion method. The crystals were cryoprotected in 20% glycerol and data collected at the Diamond Light Source on beamline i04-1 to 2.24 Å resolution at 100K. The diffraction images were integrated, scaled and reduced using the suite of program XIA2 71 with five percent of the reflections selected at random and excluded from the refinement using FREERFLAG. 72 The unit cell parameters for the crystal are a=68.3Å, b=87.3Å, c=112.2Å, α=90.0°, β=96.2°, γ=90.0° in space group P21 with four BCL-xL-AF7/BCL-XL complexes in the asymmetric unit cell. The data processing statistics are shown in Table 2 . The structure was determined by molecular replacement using the program PHASER 51 with the human BCL-XL structure (PDB code 1R2D), 73 ) and the truncated Affimer (PDB code 4N6U, 39 ) as the search models. Manual inspection of electron density maps with iterative cycles of model building and refinement were carried out using COOT 74 and REFMAC5. 75, 76 During the course of model building structural validations were carried out using the program MOLPROBITY. 77 All refinement statistics are shown in Table 2 . The structures have been deposited in the Protein Data Bank 
